|
|
Article: As the promise of diagnostic/therapeutic combinations is increasingly recognized, pharmaceutical companies must determine best practices in terms of co-marketing these combinations.
- Article from:
- M2 Presswire
- Article date:
- February 3, 2006
CopyrightCOPYRIGHT 2006 Normans Media Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
M2 PRESSWIRE-3 February 2006-Research and Markets: As the promise of diagnostic/therapeutic combinations is increasingly recognized, pharmaceutical companies must determine best practices in terms of co-marketing these combinations(C)1994-2006 M2 COMMUNICATIONS LTD
RDATE:03022006
Dublin - Research and Markets (http://www.researchandmarkets.com/reports/c32219) has announced the addition of Integrating Diagnostics and Therapeutics for Targeted Therapies, Part II: The Importance of Calculating the Return on Investment to their offering
As the promise of diagnostic/therapeutic combinations is increasingly recognized, pharmaceutical companies must ...